로딩 중…
지수 로딩 중…
테고사이언스
191420· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩7,200-3.74%
2026-06-19
Price Chart
테고사이언스-60.26%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 58.38B KRW |
| Revenue | 5.83B KRW |
| Net Income | -6.40B KRW |
| Total Assets | 75.05B KRW |
| Net Assets | 48.32B KRW |
| Employees | 39 |
| Value | |
| P/B | 1.21x |
| P/S | 10.02x |
| FCF Yield | -5.34% |
| Profitability | |
| ROE | -13.24% |
| ROA | -8.52% |
| Op. Margin | -53.15% |
| Revenue Growth | -8.69% |
| Financial Health | |
| Debt Ratio | 155.33% |
| Total Debt | 1.25B KRW |
| FCF | -3.12B KRW |
| Cash | 9.60B KRW |
| Current Ratio | 25.95x |
| Performance | |
| 1Y Return | -60.26% |
| 1M Return | -32.52% |
| From 52W High | -63.45% |
| 1Y MDD | -62.85% |
| Trading | |
| Volume | 11,507 shares |
| Foreign Own. | 1.52% |
| Per Share | |
| EPS | -1,031 KRW |
| BPS | 6,058 KRW |
Company Info
Tegosciece, established in 2001 and listed on KOSDAQ in 2014, specializes in the development, manufacturing, and sale of cell therapy products. Utilizing world-class cell culture technology, the company is a leader, holding three of 16 approved cell therapy products (Holoderm, Caloderm, Rosmir). Initially developing wound healing cell therapy products for burns and foot ulcers, Tegosciece is now expanding into regenerative medicine new drug development for musculoskeletal diseases, including domestic and U.S. clinical trials for rotator cuff tear treatment. It is headquartered in Gangseo-gu, Seoul.